Truist raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $90 from $77 and keeps a Hold rating on the shares. The company is poised for continued momentum driven by Cortrophin Gel heading into Q3, and following a record Q2 performance with $82M in sales for the product and a full-year guidance raise by 20%, the firm expects sustained growth, fueled by broader patient access and the ACTH market’s overall inflection, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares
- Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion
- ANI Pharmaceuticals price target raised to $115 from $95 at JPMorgan
- ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright
- ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim